Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01951638 · ClinicalTrials.gov registry record · Phase 2
Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure and Preserved Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-PRESERVED)
A Phase 2 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 2
- Development phase
- 477
- Enrollment target
NCT01951638: Completed Phase 2 study, sponsored by Bayer.
NCT01951638 is a Phase 2 study that has completed, run by Bayer. The registered enrollment target is 477 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (259% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01951638, a Phase 2 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 477 participants
- Enrollment target
Study Summary
Objective of the study is to find the optimal dose of the once daily oral soluble guanylate cyclase stimulator (sGC) BAY1021189 for Phase III that can be given in addition to standard diuretic and comorbidity treatment for heart failure with preserved ejection fraction (HFpEF)
Primary Outcome
NTproBNP is a circulating plasma biomarker of cardiovascular function and prognosis in heart failure (HF).
Interventions
- DRUG Placebo
- DRUG Vericiguat (BAY1021189) (1.25 mg)
- DRUG Vericiguat (BAY1021189) (5 mg)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 477 participants |
| Start Date | 2013-11-06 |
| Est. Completion | 2015-09-16 |
| Phase | Phase 2 |
What the finished NCT01951638 record still lists
NCT01951638 is an interventional study that assigns participants to a tested intervention. The registered 477 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (259% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01951638 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01951638 about?
NCT01951638 is a clinical study titled "Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure and Preserved Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-PRESERVED)". Objective of the study is to find the optimal dose of the once daily oral soluble guanylate cyclase stimulator (sGC) BAY1021189 for Phase III that can be given in addition to standard diuretic and comorbidity treatment for heart failure with preserved ejection fraction (HFpEF)
What is the current status of trial NCT01951638?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 477 participants. The study started on 2013-11-06. Estimated completion is 2015-09-16.
What interventions are being tested in trial NCT01951638?
The interventions under investigation include: Placebo (DRUG), Vericiguat (BAY1021189) (1.25 mg) (DRUG), Vericiguat (BAY1021189) (5 mg) (DRUG).
Who is sponsoring clinical trial NCT01951638?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01951638's enrollment target sits among peer trials
477 77th of 2000 higher than 1,924 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03911700 · 477 participants · NA
Prophylactic Reinforcement of Ventral Abdominal Incisions Trial
- NCT06997497 · 477 participants · Phase 3
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)
- NCT05446272 · 478 participants · NA
The Diaphragmatic Initiated Ventilatory Assist (DIVA) Trial
- NCT06172296 · 478 participants · Phase 3
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI